Drug information for NITROFURANTOIN MACROCRYSTALLINE

Form Dosage Status Therapeutic Equivalence Active Ingred Ref. Sponsor Document
CAPSULE; ORAL 50MG Discontinued   NITROFURANTOIN, MACROCRYSTALLINE Nitrofurantoin WATSON LABS 70248
CAPSULE; ORAL 100MG Discontinued   NITROFURANTOIN, MACROCRYSTALLINE Nitrofurantoin WATSON LABS 70249

Drug Adverse Effects information for NITROFURANTOIN MACROCRYSTALLINE

Role code Indications Reaction # Reports
PS CYSTITIS BACK PAIN 1
PS CYSTITIS BLOOD PRESSURE DECREASED 1
PS CYSTITIS PNEUMONIA 1
PS CYSTITIS PULMONARY TOXICITY 1
PS CYSTOSCOPY BACK PAIN 1
PS CYSTOSCOPY BLOOD PRESSURE DECREASED 1
PS CYSTOSCOPY PNEUMONIA 1
PS CYSTOSCOPY PULMONARY TOXICITY 1
PS INFECTION PROPHYLAXIS DECREASED APPETITE 1
PS INFECTION PROPHYLAXIS HYPOXIA 1
PS INFECTION PROPHYLAXIS INFLUENZA 1
PS INFECTION PROPHYLAXIS PNEUMONIA 1
PS INFECTION PROPHYLAXIS PULMONARY FIBROSIS 1
PS INFECTION PROPHYLAXIS WEIGHT DECREASED 1
SS BLOOD CHOLESTEROL INCREASED CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR 1
SS BLOOD CHOLESTEROL INCREASED NAUSEA 1
SS ORAL CANDIDIASIS CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR 1
SS ORAL CANDIDIASIS NAUSEA 1
SS SMOKING CESSATION THERAPY CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR 1
SS SMOKING CESSATION THERAPY NAUSEA 1
SS THYROID DISORDER CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR 1
SS THYROID DISORDER NAUSEA 1
SS URINARY TRACT INFECTION CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR 1
SS URINARY TRACT INFECTION NAUSEA 1
C VISUAL ACUITY REDUCED VISUAL ACUITY REDUCED 1
C VISUAL ACUITY REDUCED VITREOUS FLOATERS 1
C VITREOUS FLOATERS VISUAL ACUITY REDUCED 1
C VITREOUS FLOATERS VITREOUS FLOATERS 1
Ads by Google